SCHEMBL7075847

SCHEMBL7075847

O=C(Nc1cccc2ccccc12)[C@@H]1CCN1[Ru]Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.51
ALDH1A1 P00352 6/20 0.49
HSD17B10 Q99714 5/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TSHR P16473 1/20 0.49
HCRTR1 O43613 1/20 0.48
HCRTR2 O43614 1/20 0.48
FABP7 O15540 2/20 0.48
USP2 O75604 2/20 0.47
GAA P10253 2/20 0.47
SIGMAR1 Q99720 1/20 0.46
EPHX1 P07099 1/20 0.46
MAPK1 P28482 2/20 0.46
FABP3 P05413 1/20 0.45
EPHX2 P34913 1/20 0.45
LMNA P02545 1/20 0.44
ALOX15 P16050 1/20 0.44
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7075791 0.82 SMN1; SMN2 (0.50) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL7069088 0.78 YAP1 (0.48) ALDH1A1KMT2AMEN1HCRTR1HCRTR2
SCHEMBL6376333 0.73 HCRTR1 (0.55) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL11114114 0.71 NTMT1 (0.58) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL14503308 0.71 KDM4E (0.68) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL7072994 0.70 KMT2A (0.67) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL7072991 0.70 KMT2A (0.67) KDM4EALDH1A1HSD17B10KMT2AMEN1
SCHEMBL7075849 0.69 KMT2A (0.62) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL7075845 0.69 KMT2A (0.62) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2
SCHEMBL31098661 0.69 HTR6 (0.60) KDM4EALDH1A1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030120088-A1 Optically active azetidincarboxamide-coordinated transition metal complexes SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-26 US disclosed
EP-1319660-A1 Optically active azetidincarboxamide-coordinated transition metal complexes as catalysts in asymmetric reduction SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120088-A1 Optically active azetidincarboxamide-coordinated transition metal complexes AAAS, AP1M1, AP2A1 KDM4E 1847/4885ALDH1A1 1300/4885HSD17B10 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.